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Therapy (PDT) and best supportive care in treating patients
with AMD. METHODS: A cost-effectiveness model was created
using outcome data from the ANCHOR and MARINA clinical
trials. The model operates on quarterly cycles and a 10-year
time horizon. At baseline, Early Treatment Diabetic Retinopa-
thy Study (ETDRS) visual acuity was 55 and average age was
77 in the base case. Cost of services were obtained from the
CMS website, drug costs were obtained from ASP prices, and
visual impairment costs were based on a prospective study by
Schmier and colleagues. All costs were inﬂated to 2007 dollars
using the Health Services CPI. Utility values were based on a
time-tradeoff analysis conducted by Brown and colleagues. A
3% discount rate was used for both costs and QALYs.
RESULTS: For predominantly classic AMD, Lucentis 0.5 mg
was a dominant strategy compared to PDT and the Incremental
Cost-Effectiveness Ratio (ICER) for Lucentis 0.5 mg relative to
Lucentis 0.3 mg was $62,905/QALY. For patients with mini-
mally classic or occult AMD, Lucentis 0.5 mg was a dominant
strategy compared to best supportive care and the ICER for
Lucentis 0.5 mg relative to Lucentis 0.3 mg was $322,367/
QALY. Inﬂuential variables driving the results in this analysis
include a patient’s baseline visual acuity, costs associated with
visual impairment, and the price of Lucentis. CONCLUSION:
Despite its high treatment costs, Lucentis is a dominant strategy
compared to PDT and best supportive care primarily because it
prevents patients from reaching the highly expensive state of
blindness. Treating AMD patients with Lucentis before they
reach a legal blindness state can generate considerable cost-
savings to society.
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A COST-EFFECTIVENESS ANALYSIS OFTWOTOPICAL
OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR
THETREATMENT OF BACTERIAL CONJUNCTIVITIS
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OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of moxiﬂoxacin 5 mg/ml ophthalmic solution
(MF) to polymyxin B 10,000 units/trimethoprim 1mg/ml oph-
thalmic solution (PT) for the treatment of bacterial conjunctivitis
(BC). METHODS: Physician-assessed BC early clinical cure rates
were taken on day-2 of 7 day therapy from a multi-site, random-
ized, double-masked study comparing MF to PT. The clinical
cure rates were used to calculate a number-needed-to-treat
(NNT) estimate for the most efﬁcacious alternative. NNT was
then used as the measure of effect in an incremental cost-
effectiveness analysis. Only the direct costs of drug therapy were
considered in the economic analysis. The drug costs were derived
from a standard reference source. The economic perspective was
that of the payer. No cost discounting was performed due to the
short time horizon of BC therapy. RESULTS: Thirty-two subjects
(47 eyes) received MF and 30 subjects (43 eyes) received PT. At
baseline there were no statistical differences in BC severity or
duration, patient age, gender or ethnicity between the two treat-
ment groups. After 2 days of topical ophthalmic antibiotic
therapy, 83.3% of the MF patients were deemed clinically cured
compared to 43.2% of the PT patients. The NTT for the MF
group was estimated at 2.5. The MF incremental cost-
effectiveness ratio (ICER), the cost of curing one more BC patient
earlier, was estimated at $37.28. CONCLUSION: MF cures BC
sooner than PT thus reducing the duration of illness experienced
by BC patients. Since MF is a newer and more potent antibiotic
than PT, it incurs additional costs. The incremental cost to obtain
the additional beneﬁt of an earlier cure from MF therapy is
relatively small (< $0). Further research may demonstrate a lower
cost-effectiveness ratio from MF therapy if the indirect costs of
BC are considered.
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ECONOMIC EVALUATION OF MELOXICAM SOLUTION 0.030%
RESPECT AN OPHTHALMIC SODIUM DICLOFENAC
SOLUTION 0.1% ONTHE EYES OF PATIENTSWHO
UNDERWENTTO LASIK LASER EYE SURGERY AT
THE IMMEDIATELY POST-OPERATIVETIME
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OBJECTIVE: Compare the effectiveness and costs of the admin-
istration of an ophthalmic Meloxicam solution 0.030% with a
sodium Diclofenac solution 0.1% on the eyes of patients who
underwent to Lasik laser eye surgery at the immediately post-
operative time. METHODS: Adopting the perspective of a health
care payer, we developed a cost-effectiveness analysis. Temporary
horizon was three months. A discounting rate was not used. The
source of information of cost and effectiveness was a randomized
clinical trial. The perspective was from Mexican Institute of
social Security. The method used for cost was microcosting and
case mix. The effectiveness was measured with different end
points. The cost-effectiveness analysis was made for those vari-
ables with statistically signiﬁcant differences. The evaluation was
made with incremental analysis and net beneﬁts approach. The
sensitivity analyses was of one way, two ways and probabilistic.
RESULTS: The highest cost was with Diclofenac solution
(USD$9.29) that was 5.9% higher than Meloxicam ($8.74) the
measured efﬁcacy named Flare and ciliary injection was superior
with Meloxicam compared with Diclofenac 148 vs. 149 for Flare
and 150 vs 153 respectively (p < 0.0001) for ciliary injection, the
cost for success obtained with Meloxicam was of USD$8.74 and
USD$9.29 with Diclofenac, the incremental analysis show that
Meloxicam is dominant over Diclofenac. Health Net Beneﬁts,
Monetary Net Beneﬁts and the Acceptability curves were favour-
able for Meloxicam independent the willingness to pay.
CONCLUSION: The Meloxicam solution was dominant over
Diclofenac in the application on the ocular surface in patients
who underwent to Lasik laser eye surgery in the immediate
postoperative period. The sensitivity analysis was a robust basis
for the study.
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COST-EFFECTIVENESS OFTHE BIOLOGIC AGENTS UTILIZED
INTHETREATMENT OF CHRONIC PLAQUE PSORIASIS:
A MARKOV MODEL
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OBJECTIVE: It is the objective of this study to estimate the cost
per treatment success over a one-year timeframe of the ﬁve
biologic therapies used to treat patients with moderate to severe
psoriasis in the United States. METHODS: A Markov model was
developed to compare the relative cost components in psoriasis
treatment with biologics. Drug costs were based on wholesale
acquisition cost with consideration of net contractual discounts
and patient co-share or co-payment. Clinical efﬁcacy, for both
short-term (12 weeks) and longer-term (24+ weeks) treatment,
was based on the published peer-reviewed literature. The primary
economic endpoint was the cost of therapy (deﬁned as the cost of
drugs, laboratory, infusion, and professional services) per 75%
improvement from baseline in the Psoriasis Area and Severity
Index score (PASI 75) achieved. Analysis was conducted for each
Abstracts A289
